



DAFTAR PUSTAKA

- Antkowiak, M., Gabr, A., Das, A., Ali, R., Kulik, L., Ganger, D., Moore, C., Abecassis, M., Katariya, N., Mouli, S., Mahalingam, D., Lewandowski, R.J., Salem, R., Riaz, A. 2019. Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. *Cancers (Basel)*, 11(6):1–13.
- Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559177/>
- Azam, F., Latif, M.F., Farooq, A., Tirmazy, S.H., Alshahrani, S., Bashir, S., Bukhari, N. 2019. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. *Case Rep. Oncol*, 12(3):728–736.
- Bai, D.S., Zhang, C., Chen, P., Jin, S.J., Jiang, G.Q. 2017. The Prognostic Correlation of AFP Level at Diagnosis with Pathological Grade, Progression, and Survival of Patients with Hepatocellular Carcinoma. *Sci. Rep*, 7(1):1–9.
- Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. 2016. Hepatocellular Carcinoma: A Review. *J Hepatocell Carcinoma*. Oct;Volume 3:41–53.
- Boldo, E., Santafe, A., Mayol, A., Lozoya, R., Coret, A., Escribano, D., Fortea, C., Muñoz, A., Pastor, J.C., Pérez de Lucia, G., Bosch Aparicio, N. 2020. Rare Site Hepatocellular Carcinoma Metastasis. *J. Hepatocell. Carcinoma*, Volume 7:39–44.
- Brar, G., Greten, T.F., Graubard, B.I., McNeel, T.S., Petrick, J.L., McGlynn, K.A., Altekruse, S.F. 2020. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. *Hepatol. Commun*, 4(10):1541–1551.
- Carr, B.I., Guerra, V., G. Giannini, E., Farinati, F., Ciccarase, F., Ludovico Rapaccini, G. 2014. Association of Abnormal Plasma Billirubin with Aggressive HCC Phenotype. *Semin Oncol*, 41(2):252–258.
- Carr, B.I., Guerra, V. 2017. Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients. *Int. J. Biol. Markers*, 32(4):e391–e396.
- Carvalho, J.R., Machado, M.V. 2018. New Insights About Albumin and Liver Disease. *Ann. Hepatol*, 17(4):547–560.
- Chang, C.Y., Wei, C.Y., Chen, P.H., Hou, M.C., Chao, Y., Chau, G.Y., Lee, R.C., Huang, Y.H., Su, Y.H., Wu, J.C., Su, C.W. 2021. The Role of Albumin–Bilirubin Grade in Determining the Outcomes of Patients with Very Early-Stage Hepatocellular Carcinoma. *J. Chinese Med. Assoc*, 84(2):136–143.
- Chen, S., Li, X., Liang, Y., Lu, X., Huang, Y., Zhu, J., Li, J. 2022. Short-term Prognosis for Hepatocellular Carcinoma Patients with Lung Metastasis: A



- Retrospective Cohort Study Based on the SEER Database. *Medicine*, 101(45):e31399.
- Chi, X., Jiang, L., Yuan, Y., Huang, X., Yang, X., Hochwald, S., Liu, J., Huang, H. 2022. A Comparison of Clinical Pathologic Characteristics between Alpha-fetoprotein Negative and Positive Hepatocellular Carcinoma Patients from Eastern and Southern China. *BMC Gastroenterol*, 22(1):202.
- Cho, W.R., Hung, C.H., Chen, C.H., Lin, C.C., Wang, C.C., Liu, Y.W., Wu, Y.J., Yong, C.C., Chen, K. Den, Tsai, Y.C., Hu, T.H., Tsai, M.C. 2020. Ability of The Post-Operative ALBI Grade to Predict The Outcomes of Hepatocellular Carcinoma After Curative Surgery. *Sci. Rep*, 10(1):1–10.
- Cillo, U., Vitale, A., Grigoletto, F., Farinati, F., Brolese, A., Zanusi, G., Neri, D., Boccagni, P., Srsen, N., D’Amico, F., Ciarleglio, F.A., Bridda, A., Francesco D’Amico, D. 2006. Prospective Validation of the Barcelona Clinic Liver Cancer Staging System. *J. Hepatol.*, 44(4):723–731.
- Couto, O.F.M., Dvorchik, I., Carr, B.I. 2007. Causes of Death in Patients with Unresectable Hepatocellular Carcinoma. *Dig. Dis. Sci*, 52(11):3285–3289.
- Demirtas, C.O., D’Alessio, A., Rimassa, L., Sharma, R., Pinato, D.J. 2021. ALBI Grade: Evidence for An Improved Model for Liver Functional Estimation in Patients with Hepatocellular Carcinoma. *JHEP Reports*, 3(5):100347.
- Ding, Y., Liu, K., Xu, Y., Zhao, Q., Lou, S., Xiang, X., Yan, L., Cao, Z., Xie, Q., Zhu, C., Bao, S., Wang, H. 2020. Combination of Inflammatory Score/Liver Function and AFP Improves the Diagnostic Accuracy of HBV-related Hepatocellular Carcinoma. *Cancer Med*, 9(9):3057–3069.
- Fargo, M. V, Grogan, S.P., Saguil, A. 2017. Evaluation of Jaundice in Adults. *Am Fam Physician*, 95(3):164–168.
- Feng, D., Wang, M., Hu, J., Li, S., Zhao, S., Li, H., Liu, L. 2020. Prognostic Value of the Albumin-Bilirubin Grade in Patients with Hepatocellular Carcinoma and Other Liver Diseases. *Ann. Transl. Med*, 8(8):553.
- Gospodarowicz, M., O’Sullivan, B. 2003. Prognostic Factors in Cancer. *Semin Surg Oncol*, 21(1):13–18.
- Guerra Ruiz, A.R., Crespo, J., López Martínez, R.M., Iruzubieta, P., Casals Mercadal, G., Lalana Garcés, M., Lavin, B., Morales Ruiz, M. 2021. Measurement and Clinical Usefulness of Bilirubin in Liver Disease. *Adv. Lab. Med*, 2(3):352–361.
- Gui, B., Weiner, A.A., Noshier, J., Lu, S., Foltz, G.M., Hasan, O., Kim, S.K., Gendel, V., Mani, M.B., Carpizo, D.R., Saad, N.E., Kennedy, T.J., Zuckerman, D.A., Olsen, J.R., Parikh P.J., Jabbour, S.K. 2018. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated with Radioembolization. *Am J Clin Oncol*, 41(9):861–866.



- Hanif, H., Ali, M.J., Khan, I.W., Luna-Cuadros, M.A., Khan, M.M., Tan-Yeung Lau, D., Susheela, A.T. 2022. Update on The Applications and Limitations of Alpha-Fetoprotein for Hepatocellular Carcinoma. *World J. Gastroenterol.*, 28(2):216–229.
- Ho SY, Liu PH, Hsu CY, Hsia CY, Huang YH, Su CW, et al. 2020. A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. *Dig Dis Sci.* Feb 28;65(2):658–667.
- Hui, D. 2016. Prognostication of Survival in Patients with Advanced Cancer. *Cancer Control*, 22(4):489–497.
- Jarrar D, Wang P, Chaudry IH. Hepatocellular Dysfunction–Basic Considerations. In: Holzheimer RG, Mannick JA, editors. *Surgical Treatment: Evidence-Based and Problem-Oriented*. Munich: Zuckschwerdt; 2001. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK6886/>
- Jeng, L.B., Chan, W.L., Teng, C.F. 2023. Prognostic Significance of Serum Albumin Level and Albumin-Based Mono- and Combination Biomarkers in Patients with Hepatocellular Carcinoma. *Cancers (Basel)*, 15(4):1005.
- Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., O’Beirne, J., Fox, R., Skowronska, A., Palmer, D., Yeo, W., Mo, F., Lai, P., Iñarrairaegui, M., Chan, S.L., Sangro, B., Miksad, R., Tada, T., Kumada, T., et al. 2015. Assessment of Liver Function in Patients with Hepatocellular Carcinoma: A New Evidence-Based Approach - The ALBI Grade. *J. Clin. Oncol*, 33(6):550–558.
- Kalakonda A, Jenkins BA, John S. Physiology, Bilirubin. [Updated 2022 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470290/>
- Kariyama, K., Nouse, K., Hiraoka, A., Wakuta, A., Oonishi, A., Kuzuya, T., Toyoda, H., Tada, T., Tsuji, K., Itobayashi, E., Ishikawa, T., Takaguchi, K., Tsutsui, A., Shimada, N., Kudo, M., Kumada, T. 2020. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. *Liver Cancer*, 9(6):734–743.
- Kudo, M. 2022. Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma. *Liver Cancer*, 11(1):1–8.
- Kumar, D., Banerjee, D. 2017. Methods of Albumin Estimation in Clinical Biochemistry: Past, Present, And Future. *Clin. Chim. Acta*, 469(April):150–160.
- Kumar, P.H., Dwarka, S.S., Zahid, T., Rehman, H.U., Bains, T.S., Joseph, S.J. 2021. Causes of Death in Hepatocellular Carcinoma Patients: A SEER-Based Study, *Res. Sq*, PPR361853: 1–9. DOI: 10.21203/rs.3.rs-636132/v1.
- Kuo, Y., Wang, J., Hung, C., Rau, K., Wu, I., Chen, C., Kee, K., Hu, T., Lu, S. 2017. Albumin-Bilirubin Grade Predicts Prognosis of HCC Patients with Sorafenib Use. *J. Gastroenterol. Hepatol*, 32(12):1975–1981.



- McCance, K.L., Huether, S.E. 2019. Pathophysiology The Biologic Basis for Disease in Adult and Children. Edited by V.L. Brashers and N.S. Rote. St. Louis, Missouri: Elsevier Inc. 8th Ed., pp. 4346–4350.
- McDonagh, J., Bardell, S., Rajoriya, N., Hayes, I., Shah, T. 2024. Managing Ascites in Patients with Hepatocellular Carcinoma: Experiences from A Quaternary Liver Centre. *Gastrointest. Nurs.*, 22(Sup1):S17–S22.
- McGlynn, K.A., Petrick, J.L., El-Serag, H.B. 2021. Epidemiology of Hepatocellular Carcinoma. *Hepatology*, 73(S1):4–13.
- McPherson, R.A., Pincus, M.R. 2022. Henry's Clinical Diagnosis and Management by Laboratory Methods. Philadelphia: Elsevier Inc. 24th Ed., pp. 277–281; 316–319; 456–457.
- Mohammadi, H., Abuodeh, Y., Jin, W., Frakes, J., Friedman, M., Biebel, B., Choi, J., El-Haddad, G., Kis, B., Sweeney, J., Hoffe, S. 2018. Using the Albumin-Bilirubin (ALBI) Grade as A Prognostic Marker for Radioembolization of Hepatocellular Carcinoma. *J. Gastrointest. Oncol*, 9(5):840–846.
- Moreira, V.G., Vaktangova, N.B., Gago, M.D.M., Gonzalez, B.L., Alonso, S.G., Rodriguez, E.F. 2018. Overestimation of Albumin Measured by Bromocresol Green vs Bromocresol Purple Method: Influence of Acute-Phase Globulins. *Lab. Med*, 49(4):355–361.
- Nguyen, T.T.H., Nguyen, Van Hieu, Nguyen, Van Hung, Nguyen, T.L., Le, V.Q. 2019. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients with Hepatocellular Carcinoma in Vietnam. *Cancer Control*, 26(1):1–8.
- Ott D, Gawish A, Lux A, Heinze C, Brunner TB, Hass P. 2023. Can Alternative Liver Function Scores Facilitate the Establishment of An Indication For Radioablative Therapy in Patients With Hepatocellular Carcinoma? *J Cancer Res Clin Oncol*. Jul 16;149(8):4817–4824.
- Philips, C.A., Rajesh, S., Nair, D.C., Ahamed, R., Abduljaleel, J.K., Augustine, P. 2021. Hepatocellular Carcinoma in 2021: An Exhaustive Update. *Cureus*, 13(11): e19274.
- Pinato, D.J., Yen, C., Bettinger, D., Ramaswami, R., Arizumi, T., Ward, C., Pirisi, M., Burlone, M.E., Thimme, R., Kudo, M., Sharma, R. 2017. The Albumin–Bilirubin Grade Improves Hepatic Reserve Estimation Post-sorafenib Failure: Implications for Drug Development. *Aliment. Pharmacol. Ther*, 45(5):714–722.
- Piñero, F., Dirchwolf, M., Pessôa, M.G. 2020. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. *Cells*, 9(6):1–27.
- Rifai, N., Chiu, R.W.K., Young, I., Burnham, C.D., Wittwer, C.T. 2023. Tietz Textbook of Laboratory Medicine. St. Louis, Missouri: Elsevier Inc. 7th Ed., pp. 757–760.



- Sakamoto, Y., Shimada, S., Kamiyama, T., Sugiyama, K., Asahi, Y., Nagatsu, A., Orimo, T., Kakisaka, T., Kamachi, H., Ito, Y.M., Taketomi, A. 2022. Impact of Comorbid Renal Dysfunction in Patients with Hepatocellular Carcinoma on Long-Term Outcomes After Curative Resection. *World J. Gastrointest. Surg*, 14(7):670–684.
- Samban, S.S., Hari, A., Nair, B., Kumar, A.R., Meyer, B.S., Valsan, A., Vijayakurup, V., Nath, L.R. 2023. An Insight Into the Role of Alpha-Fetoprotein (AFP) in the Development and Progression of Hepatocellular Carcinoma. *Mol. Biotechnol.* Published online October 2, 2023. doi:10.1007/s12033-023-00890-0.
- Sastroasmoro, S., Ismael, S. 2011. Dasar-dasar Metodologi Penelitian Klinis. Jakarta: CV Sagung Seto. 4th Ed., pp. 364–367.
- Singal, A.G., Parikh, N.D., Rich, N.E., John, B. V., Pillai, A. 2019. Hepatocellular Carcinoma Surveillance and Staging. In: Hepatocellular Carcinoma: Translational Precision Medicine Approaches [Internet]. Cham (CH): Humana Press; Chapter 2. pp. 27–51. Published online 2019 Aug 6. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK553754/>
- Targe, M., Yasam, V.R., Nagarkar, R. 2021. Hepatocellular Carcinoma with Uncommon Sites of Metastasis: A Rare Case Report. *Egypt. J. Radiol. Nucl. Med.*, 52(1):228.
- Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino ÉC, da Silva RF, da Silva R de CMA, et al. Hepatocellular Carcinoma: A Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. *Asian Pacific J Cancer Prev.* 2017;18(4):863–72.
- Uka, K. 2007. Clinical Features and Prognosis of Patients With Extrahepatic Metastases from Hepatocellular Carcinoma. *World J. Gastroenterol.*, 13(3):414.
- Wang C.Y., Li, S. 2019. Clinical Characteristics and Prognosis of 2887 Patients with Hepatocellular Carcinoma: A Single Center 14 Years Experience from China. *Medicine.*; 98(4):e14070.
- Wang, X.P., Mao, M.J., He, Z.L., Zhang, L., Chi, P.D., Su, J., Dai, S.Q., Liu, W.L. 2017. A Retrospective Discussion of The Prognostic Value of Combining Prothrombin Time (PT) and Fibrinogen (Fbg) in Patients with Hepatocellular Carcinoma. *J. Cancer*, 8(11):2079–2087.
- Wang, Y.G., Wang, P., Wang, B., Fu, Z.J., Zhao, W.J., Yan, S.L. 2014. Diabetes Mellitus and Poorer Prognosis in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. *PLoS One*, 9(5):e95485.
- Wang, Y.Y., Zhong, J.H., Su, Z.Y., Huang, J.F., Lu, S.D., Xiang, B.D., Ma, L., Qi, L.N., Ou, B.N., Li, L.Q. 2016. Albumin-Bilirubin versus Child-Pugh Score as A Predictor of Outcome After Liver Resection for Hepatocellular Carcinoma. *Br. J. Surg*, 103(6):725–734.



- World Health Organization. 2021. Indonesia Source GLOBOCAN 2020. *Int. Agency Res. Cancer*. March: 1–2.
- Wu, E.M., Wong, L.L., Hernandez, B.Y., Ji, J.-F., Jia, W., Kwee, S.A., Kalathil, S. 2018. Gender Differences in Hepatocellular Cancer: Disparities in Nonalcoholic Fatty Liver Disease/Steatohepatitis and Liver Transplantation. *Hepatoma Res*, 4(10):66.
- Wu, H., Xing, H., Liang, L., Huang, B., Li, C., Lau, W.Y., Zhou, Y.-H., Gu, W.-M., Wang, H., Chen, T.-H., Zhang, Y.-M., Zeng, Y.-Y., Pawlik, T.M., Wang, M.-D., Wu, M.-C., Shen, F., Yang, T. 2019. Real-world Role of Performance Status in Surgical Resection for Hepatocellular Carcinoma: A Multicenter Study. *Eur. J. Surg. Oncol.*, 45(12):2360–2368.
- Yang, Z., Leng, K., Shi, G. 2023. Causes of Death among Patients with Hepatocellular Carcinoma in United States from 2000 to 2018. *Cancer Med*, 12(12):13076–13085.
- Yeh, H., Chiang, C.-C., Yen, T.-H. 2021. Hepatocellular Carcinoma in Patients with Renal Dysfunction: Pathophysiology, Prognosis, and Treatment Challenges. *World J. Gastroenterol*, 27(26):4104–4142.
- Yen, Y.H., Kee, K.M., Li, W.F., Liu, Y.W., Wang, C.C., Hu, T.H., Tsai, M.C., Kuo, Y.H., Lin, C.Y. 2023. Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology. *Cancers (Basel)*, 15(6):1687.